登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
ClinicalTrials.gov 上登记的一项鼻咽癌开放试验,由中山大学肿瘤防治中心牵头,本站收录的另外 21 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 22
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 牵头方(推断)中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面
- 研究中心贵州医科大学附属肿瘤医院Affiliated Cancer Hospital of Guizhou Medical University贵阳医院页面
- 研究中心广东医科大学附属医院Affiliated Hospital of Guangdong Medical University湛江医院页面
- 研究中心重庆大学附属肿瘤医院Chongqing University Cancer Hospital重庆医院页面
- 研究中心东莞市人民医院Dongguan People's Hospital东莞医院页面
- 研究中心西安交通大学第一附属医院First Affiliated Hospital of Xi'an Jiaotong University西安医院页面
- 研究中心厦门大学附属第一医院First Affiliated Hospital of Xiamen University厦门医院页面
- 研究中心佛山市第一人民医院First People's Hospital of Foshan佛山医院页面
- 研究中心福建省肿瘤医院Fujian Cancer Hospital福州医院页面
- 研究中心广西医科大学附属肿瘤医院Guangxi Medical University Cancer Hospital南宁医院页面
- 研究中心海南医学院附属医院/海南省人民医院Hainan General Hospital / Hainan Medical University hospitals海口医院页面
- 研究中心湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面
- 研究中心江苏省肿瘤医院Jiangsu Cancer Hospital南京医院页面
- 研究中心江西省肿瘤医院Jiangxi Cancer Hospital南昌医院页面
- 研究中心汕头大学医学院附属医院Shantou University Medical College hospitals汕头医院页面
- 研究中心四川省肿瘤医院Sichuan Cancer Hospital成都医院页面
- 研究中心天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面
- 研究中心华中科技大学同济医学院附属同济医院Tongji Hospital武汉医院页面
- 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面
- 研究中心四川大学华西医院West China Hospital成都医院页面
- 研究中心中南大学湘雅医院Xiangya Hospital长沙医院页面
- 研究中心浙江省肿瘤医院Zhejiang Cancer Hospital杭州医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06239727,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 65 岁;性别:不限
登记记录的入选字段
Patients with newly diagnosed, histologically confirmed nasopharyngeal carcinoma, the pathological type is non-keratinising carcinoma;
入选标准第 3 条
Tumor staged as Stage III (T3N0 Excepted; AJCC 8th);
入选标准第 4 条
Complete remission after 27 fractions of radiotherapy based on the MRI examination of the nasopharynx and neck (According to Response Evaluation Criteria in Solid Tumors 1.1);
入选标准第 10 条
Subjects with pregnancy ability must agree to use reliable contraceptive measures from screening to 1 year after treatment.
入选标准第 12 条
Active tuberculosis: active tuberculosis in the past 1 year should be excluded regardless with treatment, history of active tuberculosis over 1 year should be excluded except that previous regulatory anti-tuberculosis treatment is proved;
排除标准第 4 条
Eastern Cooperative Oncology Group performance status ≤1;
入选标准第 2 条
Normal bone marrow function: white blood cell count > 4×10\^9/L, hemoglobin > 90g/L, platelet count > 100×10\^9/L;
入选标准第 6 条
Normal liver and kidney function: total bilirubin ≤ 1.5 × upper limit of normal (ULN), alanine transaminase and aspartate transaminase ≤ 2.5 × ULN, alkaline phosphatase ≤ 2.5 × ULN, creatinine clearance rate ≥ 60 ml/min;
入选标准第 7 条
Hepatitis B virus surface antigen (HBsAg) positive and Hepatitis B virus DNA > 1000 copies/ml;
排除标准第 1 条
Anti-human immunodeficiency virus (HIV) positive or diagnosed with acquired immune deficiency syndrome (AIDS);
排除标准第 3 条
Pregnant or lactating women (pregnancy test should be considered for women with sexual life and fertility);
排除标准第 13 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06239727,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age: 18 Years to 65 Years; Eastern Cooperative Oncology Group performance status ≤1; Patients with newly diagnosed, histologically confirmed nasopharyngeal carcinoma, the pathological type is non-keratinising carcinoma; Tumor staged as Stage III (T3N0 Excepted; AJCC 8th); Patients' lymph node without adverse features (no central necrosis, no muscle/skin invasion, no lymph node fusion); Normal bone marrow function: white blood cell count > 4×10\^9/L, hemoglobin > 90g/L, platelet count > 100×10\^9/L; Normal liver and kidney function: total bilirubin ≤ 1.5 × upper limit of normal (ULN), alanine transaminase and aspartate transaminase ≤ 2.5 × ULN, alkaline phosphatase ≤ 2.5 × ULN, creatinine clearance rate ≥ 60 ml/min; Receive 3 cycles of indction chemotherapy (GP regimen + Camrelizumab); Plasma EBV DNA after the second cycle of concurrent chemotherapy: negative; Complete remission after 27 fractions of radiotherapy based on the MRI examination of the nasopharynx and neck (According to Response Evaluation Criteria in Solid Tumors 1.1); Patients must sign informed consent and be willing and able to comply with the requirements of visits, treatment, laboratory tests and other research requirements stipulated in the research schedule; Subjects with pregnancy ability must agree to use reliable contraceptive measures from screening to 1 year after treatment.排除标准:Exclusion Criteria:
Hepatitis B virus surface antigen (HBsAg) positive and Hepatitis B virus DNA > 1000 copies/ml; Anti-hepatitis C virus positive; Anti-human immunodeficiency virus (HIV) positive or diagnosed with acquired immune deficiency syndrome (AIDS); Active tuberculosis: active tuberculosis in the past 1 year should be excluded regardless with treatment, history of active tuberculosis over 1 year should be excluded except that previous regulatory anti-tuberculosis treatment is proved; Active, known or suspected autoimmune disease (including but not limited to uveitis, enteritis, hepatitis, pituitary, nephritis, vasculitis, hyperthyroidism, hypothyroidism and asthma requiring bronchiectasis). Exceptions are type I diabetes mellitus, hypothyroidism requiring hormone replacement therapy, skin disorders requiring no systemic treatment (such as vitiligo, psoriasis or alopecia); Previous interstitial lung disease or pneumonia requiring oral or intravenous steroid therapy; Chronic treatment with systemic glucocorticoid (dose equivalent to or over 10 mg prednisone per day) or any other form of immunosuppressive therapy. Subjects who used inhaled or topical corticosteroids were eligible; Uncontrolled heart disease, for example: 1) heart failure (NYHA level ≥ 2), 2) unstable angina, 3) myocardial infarction in past 1 year, 4) supraventricular or ventricular arrhythmia requiring treatment or intervention; Active infection requiring systemic treatment; Previous or concurrent with other malignant tumors, except for adequately treated non-melanoma skin cancer, cervical carcinoma in situ and thyroid papillary cancer; History of radiotherapy, except for non-melanoma skin cancer located outside the target volume of radiotherapy for nasophayngeal carcinoma; Receive treatment for the local or regional disease other than that specified in the research plan; Pregnant or lactating women (pregnancy test should be considered for women with sexual life and fertility); Allergy to macromolecular protein preparations, or any component of Camrelizumab; Receiving live vaccine within 30 days of the initial Camrelizumab; Contraindications to MRI examination, for example: claustrophobia, allergy to MRI contrast; History of psychotropic disease, alcoholism or drug abuse, and other situation assessed by the investigators that may compromise the safety or compliance of patients, such as serious disease requiring timely treatment (including mental illness), severe laboratory abnormalities, or family-social risk factors.
引自 ClinicalTrials.gov, NCT06239727, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06239727,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。